Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.63 |
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976780 | 0.83 | ALOX15 (0.58) | MAPTRAB9AKDM4ENPC1MEN1 | |
| SCHEMBL12483440 | 0.83 | GSK3B (0.53) | MAPTRAB9AKDM4ENPC1MEN1 | |
| SCHEMBL10712475 | 0.83 | MAPT (0.61) | MAPTRAB9AKDM4ENPC1MEN1 | |
| SCHEMBL38152 | 0.81 | MAPT (0.60) | MAPTRAB9AKDM4ENPC1MEN1 | |
| SCHEMBL102283 | 0.81 | KDM4E (0.53) | MAPTRAB9AKDM4ENPC1MEN1 | |
| SCHEMBL7842072 | 0.79 | ALDH1A1 (0.62) | MAPTRAB9AKDM4ENPC1MEN1 | |
| SCHEMBL15962456 | 0.79 | ALOX15 (0.47) | MAPTRAB9AKDM4ENPC1MEN1 | |
| SCHEMBL8815118 | 0.78 | MAPT (0.56) | MAPTRAB9AKDM4ENPC1MEN1 | |
| SCHEMBL6119541 | 0.78 | ALDH1A1 (0.56) | MAPTRAB9AKDM4ENPC1MEN1 | |
| SCHEMBL1883586 | 0.78 | MAPT (0.56) | MAPTRAB9AKDM4ENPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176856-A1 | Compositions and Methods for the Treatment of Norovirus Infection | UNIV INDIANA RES & TECH CORP (US) | 2016-06-23 | — | — | US | disclosed |
| US-9296719-B2 | Compositions and methods for the treatment of norovirus infection | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140235683-A1 | Compositions and Methods for the Treatment of Norovirus Infection | ALIOS BIOPHARMA INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8618115-B2 | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| EP-1948665-B1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2298776-A1 | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1948665-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007050726-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176856-A1 | Compositions and Methods for the Treatment of Norovirus Infection | NOP2, TUBB, TUBA1C | MAPT 1992/4885RAB9A 3829/4885KDM4E 4225/4885 |
| US-20140235683-A1 | Compositions and Methods for the Treatment of Norovirus Infection | NOP2, TUBB, TUBA1C | MAPT 1992/4885RAB9A 3829/4885KDM4E 4225/4885 |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | MAPT 1990/4885RAB9A 2509/4885KDM4E 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.